Cover Image

Population pharmacokinetic analysis of rivaroxaban in children and comparison to prospective physiologically‐based pharmacokinetic predictions

Abstract Rivaroxaban has been investigated in the EINSTEIN‐Jr program for the treatment of acute venous thromboembolism (VTE) in children aged 0 to 18 years and in the UNIVERSE program for thromboprophylaxis in children aged 2 to 8 years with congenital heart disease after Fontan‐procedure. Physiolo...

Full description

Saved in:

Bibliographic Details
Main Authors:	Stefan Willmann (Author), Katrin Coboeken (Author), Yang Zhang (Author), Hannah Mayer (Author), Ibrahim Ince (Author), Emir Mesic (Author), Kirstin Thelen (Author), Dagmar Kubitza (Author), Anthonie W. A. Lensing (Author), Haitao Yang (Author), Peijuan Zhu (Author), Wolfgang Mück (Author), Henk‐Jan Drenth (Author), Jörg Lippert (Author)
Format:	Book
Published:	Wiley, 2021-10-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Model‐informed bridging of rivaroxaban doses for thromboprophylaxis in pediatric patients aged 9 years and older with congenital heart disease
by: Stefan Willmann, et al.
Published: (2022)

Effect of Co-Administration of Rivaroxaban and Clopidogrel on Bleeding Time, Pharmacodynamics and Pharmacokinetics: A Phase I Study
by: Michael Becka, et al.
Published: (2012)

Enhancing the Quality of Rivaroxaban Exposure Estimates Using Prothrombin Time in the Absence of Pharmacokinetic Sampling
by: Alexander Solms, et al.
Published: (2019)

Application of Physiologically‐Based and Population Pharmacokinetic Modeling for Dose Finding and Confirmation During the Pediatric Development of Moxifloxacin
by: Stefan Willmann, et al.
Published: (2019)

Effects of ticagrelor on the pharmacokinetics of rivaroxaban in rats
by: Jia Chong, et al.
Published: (2020)

Physiologically-based pharmacokinetic modeling of tamoxifen and its metabolites in women of different CYP2D6 phenotypes provides new insight into the tamoxifen mass balance
by: Kristin eDickschen, et al.
Published: (2012)

Effects of Carbamazepine and Phenytoin on Pharmacokinetics and Pharmacodynamics of Rivaroxaban
by: Lien Thi Ngo, et al.
Published: (2020)

Application of physiologically‐based pharmacokinetic model approach to predict pharmacokinetics and drug-drug interaction of rivaroxaban: A case study of rivaroxaban and carbamazepine
by: Lien Thi Ngo, et al.
Published: (2022)

Effects of Verapamil and Diltiazem on the Pharmacokinetics and Pharmacodynamics of Rivaroxaban
by: Minsoo Kim, et al.
Published: (2019)

The discovery of rivaroxaban: translating preclinical assessments into clinical practice
by: Dagmar eKubitza, et al.
Published: (2013)

Preparation, characterization, and pharmacokinetics of rivaroxaban cocrystals with enhanced in vitro and in vivo properties in beagle dogs
by: Yuanyuan Meng, et al.
Published: (2022)

A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban
by: Frost C, et al.
Published: (2014)

Pharmacogenetics and pharmacokinetics of rivaroxaban in patients with atrial fibrillation and chronic kidney disease
by: N. A. Shatalova, et al.
Published: (2023)

A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban [Corrigendum]
by: Frost C, et al.
Published: (2018)

In vivo evaluation of the pharmacokinetic interactions between almonertinib and rivaroxaban, almonertinib and apixaban
by: Zhi Wang, et al.
Published: (2023)

Is a Lower Dose of Rivaroxaban Required for Asians? A Systematic Review of a Population Pharmacokinetics and Pharmacodynamics Analysis of Rivaroxaban
by: Xiao-Qin Liu, et al.
Published: (2023)

Pharmacokinetics, pharmacodynamics, and safety of fesomersen, a novel antisense inhibitor of factor XI, in healthy Chinese, Japanese, and Caucasian volunteers
by: Tianxing Liu, et al.
Published: (2024)

Co-Administration of Amiodarone Increases Bleeding by Affecting Rivaroxaban Pharmacokinetics in Patients with Atrial Fibrillation
by: Huamin Ding, et al.
Published: (2024)

Single and Repeated Doses of EGb 761® do not Affect Pharmacokinetics or Pharmacodynamics of Rivaroxaban in Healthy Subjects
by: Robert Hoerr, et al.
Published: (2022)

Prediction of Rivaroxaban-Rifampin Interaction After Major Orthopedic Surgery: Physiologically Based Pharmacokinetic Modeling and Simulation
by: Rui-juan Xu, et al.
Published: (2021)

Population Pharmacokinetics and Dose Optimization Based on Renal Function of Rivaroxaban in Thai Patients with Non-Valvular Atrial Fibrillation
by: Noppaket Singkham, et al.
Published: (2022)

Application of the Population Pharmacokinetics Model-Based Approach to the Prediction of Drug-Drug Interaction between Rivaroxaban and Carbamazepine in Humans
by: Lien Thi Ngo, et al.
Published: (2023)

A generic framework for the physiologically‐based pharmacokinetic platform qualification of PK‐Sim and its application to predicting cytochrome P450 3A4-mediated drug-drug interactions
by: Sebastian Frechen, et al.
Published: (2021)

A comprehensive review of the pharmacodynamics, pharmacokinetics and clinical effects of the neutral endopeptidase inhibitor racecadotril
by: Marion eEberlin, et al.
Published: (2012)

Transferability of Published Population Pharmacokinetic Models for Apixaban and Rivaroxaban to Subjects with Obesity Treated for Venous Thromboembolism: A Systematic Review and External Evaluations
by: Cyril Leven, et al.
Published: (2023)

Unravelling bisphenol A pharmacokinetics using physiologically based pharmacokinetic modeling
by: Xiaoxia eYang, et al.
Published: (2015)

Pharmacokinetic, Pharmacokinetic/Pharmacodynamic, and Safety Investigations of Lefamulin in Healthy Chinese Subjects
by: Yingying Hu, et al.
Published: (2023)

Effect of ABCB1 Gene Carriage and Drug-Drug Interactions on Apixaban and Rivaroxaban Pharmacokinetics and Clinical Outcomes in Patients with Atrial Fibrillation and Deep Vein Thrombosis
by: L. V. Fedina, et al.
Published: (2023)

Pharmacokinetics of single‐dose rivaroxaban under fed state in obese vs. non‐obese subjects: An open‐label controlled clinical trial (RIVOBESE‐PK)
by: Majdoleen Alalawneh, et al.
Published: (2024)

Pharmacokinetics, Safety and Pharmacokinetics/Pharmacodynamics Analysis of Omadacycline in Chinese Healthy Subjects
by: Haijing Yang, et al.
Published: (2022)

First-in-human study to investigate the safety and pharmacokinetics of salvianolic acid A and pharmacokinetic simulation using a physiologically based pharmacokinetic model
by: Jinliang Chen, et al.
Published: (2022)

Apixaban and rivaroxaban's physiologically‐based pharmacokinetic model validation in hospitalized patients: A first step for larger use of a priori modeling approach at bed side
by: Jean Terrier, et al.
Published: (2023)

Clinical Pharmacokinetics of Semaglutide: A Systematic Review
by: Yang XD, et al.
Published: (2024)

Pharmacokinetics of Chinese medicines: strategies and perspectives
by: Ru Yan, et al.
Published: (2018)

Data‐driven personalization of a physiologically based pharmacokinetic model for caffeine: A systematic assessment
by: Rebekka Fendt, et al.
Published: (2021)

Physiologically based pharmacokinetic modeling to predict the pharmacokinetics of codeine in different CYP2D6 phenotypes
by: Yujie Yang, et al.
Published: (2024)

Population pharmacokinetic study of the effect of polymorphisms in the ABCB1 and CES1 genes on the pharmacokinetics of dabigatran
by: Zhuan Yang, et al.
Published: (2024)

Pharmacokinetic study on the effect of ligustrazine-tangeretin co‐administration on the pharmacokinetics of ligustrazine and its potential mechanism in rats
by: Dandan Liu, et al.
Published: (2023)

Rituximab pharmacokinetic and pharmacokinetic-pharmacodynamic evaluation based on a study in diffuse large B‐cell lymphoma: Influence of tumor size on pharmacokinetic and assessment of pharmacokinetic similarity
by: Robin J. Svensson, et al.
Published: (2023)

Evaluation of pharmacokinetics of warfarin from validated pharmacokinetic-pharmacodynamic model
by: Kannan Sridharan, et al.
Published: (2021)